中国医学前沿杂志（电子版）2024，Vol.16Issue(2)：88-93,6.DOI:10.12037/YXQY.2024.02-13
成人复发/难治性费城染色体阳性急性淋巴细胞白血病的免疫治疗进展
Immunotherapy advances in adult patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
摘要
Abstract
Combination of tyrosine kinase inhibitor(TKI)and standard chemotherapy has greatly improved the prognosis of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+-ALL).Three-year overall survival(OS)rate of Ph+-ALL patients treated with chemotherapy combined with first-generation or second-generation TKI was approximately 40%-60%,and 6-year OS approached 75%when combined with the third-generation TKI ponatinib.However,2-year OS of patients with relapsed/refractory Ph+-ALL(R/R Ph+-ALL)was only 20%with a salvage therapy,indicating new treatment strategies are on demand,such as immunotherapy.Immunotherapies mainly utilize targeted antibodies including blinatumomab(anti-CD3 and CD19 bispecific antibodies),inotuzumab-ozogamicin(anti-CD22 monoclonal antibodies),and chimeric antigen receptor T-cell(CAR-T)therapy targeted antigen CD19.However,due to the limited improvement in long-term outcome from immunotherapy,a bridged allogeneic hematopoietic stem cell transplantation(allo-HSCT)was generally recommended after immunotherapy with complete remission.At present,some studies have shown that allo-HSCT was able to reduce relapse rate in Ph+-ALL,however,the improvement of overall survival produced by allo-HSCT after immunotherapy presented a controversial opinion nowadays.So further exploration of a bridged allo-HSCT post immunotherapy for R/R Ph+-ALL will be needed.This review mainly discussed the significant progress of immunotherapy in adult patients with relapsed/refractory Ph+-ALL in recent years,hoping to improve the remission rate and prognosis of patients with relapsed/refractory Ph+-ALL.关键词
费城染色体急性淋巴细胞白血病/免疫治疗/异基因造血干细胞移植Key words
Philadelphia chromosome-positive acute lymphoblastic leukemia/Immunotherapy/Allogeneic hematopoietic stem cell transplantation引用本文复制引用
孙倩倩,谢芳,闫凡芝,闫金松..成人复发/难治性费城染色体阳性急性淋巴细胞白血病的免疫治疗进展[J].中国医学前沿杂志（电子版）,2024,16(2):88-93,6.基金项目
Liaoning province governmental guidance fund for local development of science and technology(5021019) 辽宁省中央引导地方科技发展资金(5021019) （5021019）
